Mirabegron Ratiopharm

Mirabegron, the active ingredient in Mirabegron Ratiopharm, is a β3‑adrenergic receptor agonist presented as an oral dosage form for oral use. It is indicated for the treatment of overactive bladder symptoms such as urgency, frequency and urge incontinence in adults. GNH USA supplies Mirabegron Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirabegron acts on the β3‑adrenergic pathway to improve bladder storage function in patients with overactive bladder. - Overactive bladder: increases bladder capacity and reduces urgency episodes. - Urinary urgency: lessens the sudden need to void. - Urinary frequency: decreases the number of daily voids. - Urge urinary incontinence: reduces involuntary leakage associated with urgency.

Adverse reactions may occur with mirabegron therapy.

Common Side Effects: - Hypertension: elevated blood pressure observed in some patients. - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Headache: transient head discomfort. - Constipation: reduced bowel motility.

Serious or Rare Side Effects: - Severe hypertension: marked increase in blood pressure requiring medical intervention. - Urinary retention: inability to empty the bladder, potentially needing catheterisation. - Angioedema: swelling of face, lips or throat. - Myocardial infarction: rare occurrence of heart attack.

Before initiating therapy, clinicians should evaluate patient-specific risk factors and monitor for adverse events. - Blood pressure assessment: measure baseline and periodically during treatment. - Cardiovascular monitoring: watch for signs of hypertension or arrhythmia. - Renal function: adjust use in severe renal impairment. - Hypersensitivity: discontinue if allergic reactions develop. - Drug interactions: review concomitant medications for potential interactions. - Store at below 25°C: keep in the original pack, protect from moisture.

Mirabegron may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors: may increase mirabegron plasma levels. - Strong CYP3A4 inhibitors: can raise exposure and risk of hypertension. - Anticholinergic agents: may exacerbate urinary retention.

Moderate Interactions (Monitor Closely):\n- Moderate CYP2D6 inhibitors: may modestly increase mirabegron concentrations. - Diuretics: concurrent use may affect fluid balance and blood pressure. - CYP3A4 inducers: may reduce mirabegron effectiveness. - Other antihypertensives: monitor blood pressure for additive effects.